These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 20579747)

  • 1. Signaling pathways in schizophrenia: emerging targets and therapeutic strategies.
    Karam CS; Ballon JS; Bivens NM; Freyberg Z; Girgis RR; Lizardi-Ortiz JE; Markx S; Lieberman JA; Javitch JA
    Trends Pharmacol Sci; 2010 Aug; 31(8):381-90. PubMed ID: 20579747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action.
    Freyberg Z; Ferrando SJ; Javitch JA
    Am J Psychiatry; 2010 Apr; 167(4):388-96. PubMed ID: 19917593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Concepts in Dopamine D
    Urs NM; Peterson SM; Caron MG
    Biol Psychiatry; 2017 Jan; 81(1):78-85. PubMed ID: 27832841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic treatment and neuregulin 1-ErbB4 signalling in schizophrenia.
    Pan B; Huang XF; Deng C
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):924-30. PubMed ID: 21513767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The search for novel antipsychotics: pharmacological and molecular targets.
    Sanger DJ
    Expert Opin Ther Targets; 2004 Dec; 8(6):631-41. PubMed ID: 15584867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conditioned avoidance response in the development of new antipsychotics.
    Wadenberg ML
    Curr Pharm Des; 2010 Jan; 16(3):358-70. PubMed ID: 20109144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging therapeutic targets for schizophrenia: a framework for novel treatment strategies for psychosis.
    Sonnenschein SF; Grace A
    Expert Opin Ther Targets; 2021 Jan; 25(1):15-26. PubMed ID: 33170748
    [No Abstract]   [Full Text] [Related]  

  • 8. Schizophrenia: treatment targets beyond monoamine systems.
    Ibrahim HM; Tamminga CA
    Annu Rev Pharmacol Toxicol; 2011; 51():189-209. PubMed ID: 20868275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotic drug actions on gene modulation and signaling mechanisms.
    Molteni R; Calabrese F; Racagni G; Fumagalli F; Riva MA
    Pharmacol Ther; 2009 Oct; 124(1):74-85. PubMed ID: 19540875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment.
    Snyder GL; Vanover KE
    Curr Pharm Des; 2014; 20(31):5093-103. PubMed ID: 24345266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipsychotic drug action: antagonism, inverse agonism or partial agonism.
    Strange PG
    Trends Pharmacol Sci; 2008 Jun; 29(6):314-21. PubMed ID: 18471899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.
    Lieberman JA; Bymaster FP; Meltzer HY; Deutch AY; Duncan GE; Marx CE; Aprille JR; Dwyer DS; Li XM; Mahadik SP; Duman RS; Porter JH; Modica-Napolitano JS; Newton SS; Csernansky JG
    Pharmacol Rev; 2008 Sep; 60(3):358-403. PubMed ID: 18922967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic utility of NK3 receptor antagonists for the treatment of schizophrenia.
    Dawson LA; Smith PW
    Curr Pharm Des; 2010 Jan; 16(3):344-57. PubMed ID: 20109143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.
    Howes OD; Egerton A; Allan V; McGuire P; Stokes P; Kapur S
    Curr Pharm Des; 2009; 15(22):2550-9. PubMed ID: 19689327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention.
    Gomes FV; Grace AA
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine receptor heteromers: biasing antipsychotics.
    Sahlholm K; Valle-León M; Fernández-Dueñas V; Ciruela F
    Future Med Chem; 2018 Dec; 10(23):2675-2677. PubMed ID: 30518245
    [No Abstract]   [Full Text] [Related]  

  • 17. Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia.
    Lodge DJ; Grace AA
    Trends Pharmacol Sci; 2011 Sep; 32(9):507-13. PubMed ID: 21700346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
    Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
    Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PDE Inhibitors for the Treatment of Schizophrenia.
    Snyder GL; Vanover KE
    Adv Neurobiol; 2017; 17():385-409. PubMed ID: 28956340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The search of targets for novel antipsychotic drugs.
    Takano A
    Curr Pharm Des; 2010 Jan; 16(3):308. PubMed ID: 20109140
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.